Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
216.17
+4.28 (+2.02%)
Streaming Delayed Price
Updated: 11:46 AM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
39
40
Next >
Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
August 17, 2021
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and...
Via
Benzinga
Analyst Ratings for Biogen
August 02, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the...
Via
Benzinga
Expert Ratings For Biogen
July 23, 2021
Within the last quarter, Biogen (NASDAQ:BIIB) has observe...
Via
Benzinga
Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2
August 17, 2021
Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (...
Via
Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
August 16, 2021
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What...
Via
Benzinga
Exposures
COVID-19
Large Cap Biopharma Stocks provide Growth and Value
August 16, 2021
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
Is There Any Hope Left for This Alzheimer's Drug Developer?
August 13, 2021
Biogen is reeling from charges that its drug doesn't work.
Via
The Motley Fool
How Much Should An Alzheimer's Drug Cost?
August 13, 2021
The answer is more complicated than you think.
Via
The Motley Fool
Cassava Sciences vs. Biogen
August 12, 2021
Who will emerge victorious in the race to help Alzheimer's patients?
Via
The Motley Fool
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
August 12, 2021
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:...
Via
Benzinga
What to Do After Cassava Sciences Dropped Off a Cliff
August 09, 2021
Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop.
Via
InvestorPlace
Why I Sold My Biogen Stock
August 05, 2021
It has everything to do with Aduhelm.
Via
The Motley Fool
Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?
July 31, 2021
Probably.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Is Now a Good Time to Buy Biogen Stock?
July 30, 2021
It's a definite maybe.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Why Biogen's Stock Has Likely Peaked
July 30, 2021
The stock has a tough road back to $400, assuming it can get back there at all.
Via
The Motley Fool
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
July 29, 2021
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases...
Via
Benzinga
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
July 29, 2021
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
Via
Investor's Business Daily
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
July 29, 2021
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
Via
The Motley Fool
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
July 29, 2021
FDA approval of roxadustat seems unlikely.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Product Safety
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
July 27, 2021
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild...
Via
Benzinga
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
July 27, 2021
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Could These 3 Potential Blockbusters Transform Biogen?
July 25, 2021
The company is moving into three billion-dollar areas.
Via
The Motley Fool
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
July 23, 2021
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.
Via
Investor's Business Daily
Stock Market Rally Rebounds To Highs; Snap, Crocs, Chipotle, Netflix Are Key Earnings
July 23, 2021
The market rally rebounded from Monday, with the S&P 500 hitting a record high. Snap, Crocs, Chipotle were earnings winners
Via
Investor's Business Daily
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
Investors Too Gloomy Over Biogen Alzheimer’s Drug
July 23, 2021
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better.
Via
Talk Markets
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
July 22, 2021
BIIB earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.